Literature DB >> 27451408

Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport.

Priyanka Kulkarni1, Kenneth Korzekwa1, Swati Nagar2.   

Abstract

Accurate prediction of drug target activity and rational dosing regimen design require knowledge of drug concentrations at the target. It is important to understand the impact of processes such as membrane permeability, partitioning, and active transport on intracellular drug concentrations. The present study aimed to predict intracellular unbound atorvastatin concentrations and characterize the effect of enzyme-transporter interplay on these concentrations. Single-pass liver perfusion studies were conducted in rats using atorvastatin (ATV, 1 µM) alone at 4°C and at 37°C in presence of rifampin (RIF, 20 µM) and 1-aminobenzotriazole (ABT, 1 mM), separately and in combination. The unbound intracellular ATV concentration was predicted with a five-compartment explicit membrane model using the parameterized diffusional influx clearance, active basolateral uptake clearance, and metabolic clearance. Chemical inhibition of uptake and metabolism at 37°C proved to be better controls relative to studies at 4°C. The predicted unbound intracellular concentration at the end of the 50-minute perfusion in the +ABT , +ABT+RIF, and the ATV-only groups was 6.5 µM, 0.58 µM, and 5.14 µM, respectively. The predicted total liver concentrations and amount recovered in bile were within 0.94-1.3 fold of the observed value in all groups. The fold difference in total liver concentration did not always extrapolate to the fold difference in predicted unbound concentration across groups. Together, these results support the use of compartmental modeling to predict intracellular concentrations in dynamic organ-based systems. These predictions can provide insight into the role of uptake transporters and metabolizing enzymes in determining drug tissue concentrations.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27451408      PMCID: PMC5034709          DOI: 10.1124/jpet.116.235689

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  59 in total

1.  Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.

Authors:  Wakaba Yamashiro; Kazuya Maeda; Masakazu Hirouchi; Yasuhisa Adachi; Zhuohan Hu; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2006-04-19       Impact factor: 3.922

2.  Multispecific amphipathic substrate transport by an organic anion transporter of human liver.

Authors:  X Bossuyt; M Müller; P J Meier
Journal:  J Hepatol       Date:  1996-11       Impact factor: 25.083

3.  Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.

Authors:  Wei Zhang; Yi-Jing He; Chun-Ting Han; Zhao-Qian Liu; Qing Li; Lan Fan; Zhi-Rong Tan; Wei-Xia Zhang; Bang-Ning Yu; Dan Wang; Dong-Li Hu; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

4.  Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.

Authors:  Lawrence D Mayer; Kye-Taek Lim; Daria Hartley
Journal:  J Exp Ther Oncol       Date:  2002 Mar-Apr

5.  Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements.

Authors:  Anna-Karin Sohlenius-Sternbeck
Journal:  Toxicol In Vitro       Date:  2006-06-29       Impact factor: 3.500

6.  Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution.

Authors:  R F Reinoso; B A Telfer; B S Brennan; M Rowland
Journal:  Drug Metab Dispos       Date:  2001-04       Impact factor: 3.922

7.  Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.

Authors:  Xiaoqiang Xiang; Srinivasa Rao Jada; Hui Hua Li; Lu Fan; Lai San Tham; Chiung Ing Wong; Soo Chin Lee; Robert Lim; Qing Yu Zhou; Boon Cher Goh; Eng Huat Tan; Balram Chowbay
Journal:  Pharmacogenet Genomics       Date:  2006-09       Impact factor: 2.089

8.  Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.

Authors:  A L Mazzu; K C Lasseter; E C Shamblen; V Agarwal; J Lettieri; P Sundaresen
Journal:  Clin Pharmacol Ther       Date:  2000-10       Impact factor: 6.875

9.  A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.

Authors:  B Hsiang; Y Zhu; Z Wang; Y Wu; V Sasseville; W P Yang; T G Kirchgessner
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

10.  Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.

Authors:  Alexander Treiber; Ralph Schneiter; Stephanie Häusler; Bruno Stieger
Journal:  Drug Metab Dispos       Date:  2007-05-11       Impact factor: 3.922

View more
  10 in total

1.  Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.

Authors:  Swati Nagar; Richard C Korzekwa; Ken Korzekwa
Journal:  Mol Pharm       Date:  2017-07-31       Impact factor: 4.939

2.  A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats.

Authors:  Priyanka Kulkarni; Ken Korzekwa; Swati Nagar
Journal:  Xenobiotica       Date:  2019-10-01       Impact factor: 1.908

3.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

4.  Prediction of Tissue-Plasma Partition Coefficients Using Microsomal Partitioning: Incorporation into Physiologically based Pharmacokinetic Models and Steady-State Volume of Distribution Predictions.

Authors:  Kimberly Holt; Min Ye; Swati Nagar; Ken Korzekwa
Journal:  Drug Metab Dispos       Date:  2019-07-19       Impact factor: 3.922

5.  Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.

Authors:  Yingying Guo; Xiaoyan Chu; Neil J Parrott; Kim L R Brouwer; Vicky Hsu; Swati Nagar; Pär Matsson; Pradeep Sharma; Jan Snoeys; Yuichi Sugiyama; Daniel Tatosian; Jashvant D Unadkat; Shiew-Mei Huang; Aleksandra Galetin
Journal:  Clin Pharmacol Ther       Date:  2018-09-12       Impact factor: 6.875

6.  Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Mol Pharm       Date:  2018-04-10       Impact factor: 4.939

7.  Cellular Pharmacokinetic Model-Based Analysis of Genistein, Glyceollin, and MK-571 Effects on 5 (and 6)-Carboxy-2',7'-Dichloroflourescein Disposition in Caco-2 Cells.

Authors:  Callie Drennen; Erin Gorse; Robert E Stratford
Journal:  J Pharm Sci       Date:  2017-12-14       Impact factor: 3.534

8.  Methods to Predict Volume of Distribution.

Authors:  Kimberly Holt; Swati Nagar; Ken Korzekwa
Journal:  Curr Pharmacol Rep       Date:  2019-06-06

9.  Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.

Authors:  Jaydeep Yadav; Mehdi El Hassani; Jasleen Sodhi; Volker M Lauschke; Jessica H Hartman; Laura E Russell
Journal:  Drug Metab Rev       Date:  2021-05-25       Impact factor: 6.984

10.  Using partition analysis as a facile method to derive net clearances.

Authors:  Ken Korzekwa; Jaydeep Yadav; Swati Nagar
Journal:  Clin Transl Sci       Date:  2022-06-02       Impact factor: 4.438

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.